Authors: M. Lukáš Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze Published in: Gastroent Hepatol 2025; 79(1): 55-56 Category: Drug Profile doi: https://doi.org/10.48095/ccgh202555
1. ClinicalTrial.gov. Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects. 2021 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT04428814?term=CT-P43& checkSpell=false&rank=2.
2. ClinicalTrial.gov. A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis. 2023 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT04673786?term=CT-P43&checkSpell=false&rank=1.
3. Papp KA, Lebwohl MG, Thaci D et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28 week results of a randomized, active controlled, double blind, phase III study. BioDrugs 2024; 38 (1): 121–131. doi: 10.1007/s40259-023-00630-5.
Korespondenční autor
prof. MUDr. Milan Lukáš, CSc., AGAF
Klinické a výzkumné centrum pro střevní záněty
Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Českomoravská 19
190 00 Praha 9
milan.lukas@email.cz
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
